Company profile

Richard B. Hancock
Incorporated in
Fiscal year end
Former names
Peregrine Pharmaceuticals Inc, Techniclone Corp, Techniclone International Corp
IRS number

CDMO stock data



27 Jun 19
25 Aug 19
30 Apr 20


Company financial data Financial data

Quarter (USD) Apr 19 Jan 19 Oct 18 Jul 18
Revenue 17.06M 13.78M 10.18M 12.59M
Net income 336K -1.14M -1.45M -1.96M
Diluted EPS -0.02 -0.05 -0.05 -0.05
Net profit margin 1.97% -8.27% -14.26% -15.58%
Operating income 75K -1.19M -2.48M -2.02M
Net change in cash 4.59M -4.94M -4.79M -4.78M
Cash on hand 32.35M 27.76M 32.69M 37.48M
Cost of revenue 13.41M 11.73M 9.84M 11.4M
Annual (USD) Apr 19 Apr 18 Apr 17 Apr 16
Revenue 53.6M 53.62M 57.63M 44.36M
Net income -4.22M -21.81M -28.16M -55.65M
Diluted EPS -0.16 -0.56 -0.88 -1.95
Net profit margin -7.86% -40.68% -48.86% -125%
Operating income -5.62M -20.64M 1.29M 3.49M
Net change in cash -9.91M -4.53M -14.61M -6.59M
Cash on hand 32.35M 42.27M 46.8M 61.41M
Cost of revenue 46.38M 56.55M 38.26M 22.97M

Financial data from company earnings reports

Financial report summary

Management Discussion
  • Revenues were $53,603 in fiscal 2019 and were flat compared to $53,621 in fiscal 2018. In late fiscal 2018 we secured several new customers who contributed significantly to revenue in fiscal 2019. Our incremental revenues recognized from a more diversified customer base were offset by a reduction in manufacturing demand from our, historically, two largest customers. The net change in revenue was attributed to the following components, represented as a percentage of revenue:
  • Gross profit was $7,224 in fiscal 2019 compared to a gross loss of $2,924 in fiscal 2018, an increase of $10,148 primarily due to the variability of manufacturing costs from product to product. Gross margins were a positive 13.5% and a negative 5.5%, respectively. Excluding the $3,500 favorable impact from the adoption of ASC 606, the increase in gross profit was attributable to decreased manufacturing labor and overhead costs and the variability of manufacturing costs from product to product.
  • SG&A expenses were $12,846 in fiscal 2019 compared to $16,456 in fiscal 2018, a decrease of $3,610 or 22%. As a percentage of revenue, SG&A expenses for the fiscal years 2019 and 2018 were 24.0% and 30.7%, respectively. The net decrease in SG&A expenses were attributed to the following components:
Content analysis ?
H.S. junior Avg
New words: absorption, anniversary, area, biennial, capitalin, chain, COBRA, codified, composed, condensed, copy, Daniel, deprecation, expedient, family, flat, Footprint, forfeited, Hart, incremental, Intraperiod, legacy, length, ninety, noncash, people, pro, proportional, rata, reader, RSU, salary, settled, stream, street, Subtotal, surrendered, text, theInternal, throughput, unbilled, unconditional, unsatisfied
Removed: accelerated, age, al, allegedly, allocable, analyzed, application, approving, attestation, back, bid, breached, candor, Cap, captionedMichaeli, Codification, collected, committed, compromise, conclusion, consecutive, consistent, contemporaneously, defendant, deliverable, delivered, difficulty, discovery, diversity, divided, division, doubled, doubt, earlier, eastern, enabling, exist, false, final, fulfill, generating, identified, improper, insufficient, investigational, IRS, ix, judgement, King, lattice, leaseback, leasing, lessee, lesser, letter, licensor, LP, measure, Midcap, misleading, MLV, modify, monitoring, Noble, nonconsecutive, Oxford, predictable, purportedly, ready, refocused, reliance, remained, rental, representing, requirement, retrospectively, satisfying, SBIC, Science, separable, setting, shelf, shipment, Silicon, simplify, slightly, Steven, submission, submit, subsidiary, substantive, supplement, supplemental, supporting, thereof, title, unchanged, undelivered, unusable, user, valid, Valley, vendor, vested, vi, vii, viii, VSOE, warrant